DaVita Inc. (NYSE:DVA) Position Increased by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 31.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 164,016 shares of the company's stock after acquiring an additional 38,936 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.20% of DaVita worth $26,887,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of DVA. Harvard Management Co. Inc. acquired a new position in DaVita in the second quarter valued at $55,115,000. Lazard Asset Management LLC increased its position in shares of DaVita by 147.3% in the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company's stock valued at $35,460,000 after buying an additional 153,008 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in DaVita during the 2nd quarter valued at about $9,615,000. KBC Group NV increased its holdings in DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company's stock valued at $51,395,000 after acquiring an additional 67,250 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in DaVita during the 3rd quarter valued at about $10,346,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Trading Up 0.8 %

DVA stock traded up $1.37 during midday trading on Friday, reaching $165.51. 612,123 shares of the company's stock traded hands, compared to its average volume of 1,021,709. The company has a market capitalization of $13.57 billion, a P/E ratio of 17.85, a PEG ratio of 0.93 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a fifty-two week low of $98.26 and a fifty-two week high of $168.50. The business has a 50-day moving average price of $158.31 and a two-hundred day moving average price of $148.29.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company's revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.85 EPS. Equities research analysts forecast that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DVA. UBS Group lifted their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. Truist Financial lifted their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a report on Monday, October 7th. Bank of America lifted their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a report on Wednesday, August 7th. Finally, Barclays raised their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $161.80.

Insider Activity

In related news, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. The trade was a 36.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Javier Rodriguez sold 9,881 shares of DaVita stock in a transaction on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the sale, the chief executive officer now owns 887,835 shares of the company's stock, valued at approximately $144,583,929.75. This trade represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 156,086 shares of company stock worth $24,807,161 over the last 90 days. Company insiders own 2.00% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.